AUTL
Autolus Therapeutics plc
Key Financials
Operating Income
$-270544000
↓ 12.1%
Revenue
$75.4M
↑ 644.9%
Net Income
$-287528000
↓ 30.3%
Total Liabilities
$410.9M
↑ 15.6%
Shareholders' Equity
$178.1M
↓ 58.3%
Cash & Equivalents
$104.1M
↓ 54.2%
EPS (Diluted)
$-1.08
↓ 25.6%
Total Assets
$589.1M
↓ 24.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| EFFECT | 9/22/2026 | View on SEC |
| 424B3 | 9/22/2026 | View on SEC |
| DEL AM | 9/15/2026 | View on SEC |
| S-3 | 9/14/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 144 | 9/2/2026 | View on SEC |
| SCHEDULE 13D/A | 8/28/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AUTL |
| Company Name | Autolus Therapeutics plc |
| CIK | 1730463 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | X0 |
| Phone | 44 20 3829 6230 |